Blackhawk Capital Partners LLC. increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 190.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,176 shares of the medical research company's stock after buying an additional 1,427 shares during the quarter. Blackhawk Capital Partners LLC.'s holdings in Bio-Rad Laboratories were worth $715,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of BIO. Venturi Wealth Management LLC grew its stake in shares of Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after acquiring an additional 87 shares in the last quarter. Gladius Capital Management LP acquired a new position in Bio-Rad Laboratories during the third quarter worth $32,000. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the fourth quarter valued at $33,000. UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in Bio-Rad Laboratories during the 3rd quarter worth about $55,000. Institutional investors and hedge funds own 65.24% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently weighed in on BIO shares. Royal Bank of Canada restated an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Citigroup raised their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $395.20.
Read Our Latest Report on Bio-Rad Laboratories
Bio-Rad Laboratories Stock Performance
Shares of BIO traded down $1.03 during mid-day trading on Friday, reaching $264.60. The company's stock had a trading volume of 301,776 shares, compared to its average volume of 231,866. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 1-year low of $262.11 and a 1-year high of $387.99. The business has a 50-day simple moving average of $328.27 and a two-hundred day simple moving average of $332.89. The stock has a market cap of $7.41 billion, a P/E ratio of -4.07 and a beta of 0.90.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.
Bio-Rad Laboratories Company Profile
(
Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Read More
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
